Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Real-life multicenter Italian study in relapsed Waldenström macroglobulinemia finds ORR 84.7% in ibrutinib group vs 74.6% in non-BTKi group; at 4 years 68% patients responding at 4 years w/ ibrutinib vs. 50% for non-BTKi.”
Title: Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström Macroglobulinaemia? A real-life multicentre Italian study
Authors: Francesco Autore, Alessandra Tedeschi, Giulia Benevolo, Nicolò Danesin, Diana Giannarelli, Rita Rizzi, Emanuele Cencini, Veronica Mattiello, Isacco Ferrarini, Raffaella Pasquale, Ilaria Del Giudice, Angela Ferrari, Martina Bullo, Bernardo Rossini, Marina Motta, Dario Marino, Idanna Innocenti, Luca Stirparo, Diego Petrilli, Pellegrino Musto, Veronica Peri, Giulia Zamprogna, Stefan Hohaus, Anna Maria Frustaci, Francesco Piazza, Simone Ferrero, Luca Laurenti
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
